# Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

Study · id `cardio:ct-nct01972178` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01972178](<https://clinicaltrials.gov/study/NCT01972178>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01972178

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 113 participants.

## Technical summary

Registry record NCT01972178. Randomized; double masking; primary purpose treatment. Start 2013-11 (registry gives no type); primary completion 2014-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 113 participants (enrolled count; ClinicalTrials.gov record NCT01972178, source copy `cardio:ctgov-nct01972178-2015-10-30`, retrieved 2026-10-31)
- Start date: 2013-11 (registry gives no type) (ClinicalTrials.gov record NCT01972178, source copy `cardio:ctgov-nct01972178-2015-10-30`, retrieved 2026-10-31)
- Primary completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01972178, source copy `cardio:ctgov-nct01972178-2015-10-30`, retrieved 2026-10-31)
- Completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01972178, source copy `cardio:ctgov-nct01972178-2015-10-30`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01972178, source copy `cardio:ctgov-nct01972178-2015-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01972178-2015-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia
- Condition: Dyslipidemia
- Intervention (Drug): PRC-4016
- Intervention (Drug): Placebo
- Intervention (Drug): Statins
- Lead sponsor: Pronova BioPharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Statins (`cardio:statins`)

## Provenance

Content hash: 540fae9737c6db254ae2e2b75e4b3d10ff4bcbb12294cf663f2fc8847f686616
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
